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Regulation of transforming growth factor-b (TGF-b) signaling is critical in vertebrate development, as several members
of the TGF-b family have been shown to act as morphogens, controlling a variety of cell fate decisions depending on
concentration. Little is known about the role of intracellular regulation of the TGF-b pathway in development. E3
ubiquitin ligases target specific protein substrates for proteasome-mediated degradation, and several are implicated in
signaling. We have shown that Arkadia, a nuclear RING-domain E3 ubiquitin ligase, is essential for a subset of Nodal
functions in the embryo, but the molecular mechanism of its action in embryonic cells had not been addressed. Here,
we find that Arkadia facilitates Nodal signaling broadly in the embryo, and that it is indispensable for cell fates that
depend on maximum signaling. Loss of Arkadia in embryonic cells causes nuclear accumulation of phospho-Smad2/3
(P-Smad2/3), the effectors of Nodal signaling; however, these must be repressed or hypoactive as the expression of
their direct target genes is reduced or lost. Molecular and functional analysis shows that Arkadia interacts with and
ubiquitinates P-Smad2/3 causing their degradation, and that this is via the same domains required for enhancing their
activity. Consistent with this dual function, introduction of Arkadia in homozygous null ( / ) embryonic stem cells
activates the accumulated and hypoactive P-Smad2/3 at the expense of their abundance. Arkadia /  cells, like
Smad2 / cells, cannot form foregut and prechordal plate in chimeras, confirming this functional interaction in vivo. As
Arkadia overexpression never represses, and in some cells enhances signaling, the degradation of P-Smad2/3 by
Arkadia cannot occur prior to their activation in the nucleus. Therefore, Arkadia provides a mechanism for signaling
termination at the end of the cascade by coupling degradation of P-Smad2/3 with the activation of target gene
transcription. This mechanism can account for achieving efficient and maximum Nodal signaling during embryogenesis
and for rapid resetting of target gene promoters allowing cells to respond to dynamic changes in extracellular signals.
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Introduction
Transforming growth factor-b (TGF-b) signaling controls a
diverse set of cellular processes, including cell proliferation,
differentiation, apoptosis, and speciﬁcation of fate in
vertebrate and invertebrate species. Disruption of signaling
leads to developmental abnormalities and disease, including
cancer. Activin and Nodal TGF-b ligands have been shown to
act as morphogens in vertebrate development [1–4]. For
example, in the mouse, Nodal is required for gastrulation,
including development of the anterior primitive streak and
the formation of the germ layers, endoderm and mesoderm
[5,6]; for maintenance of pluripotency in the epiblast [7,8];
and for the speciﬁcation of the anterior-posterior [9,10] and
left-right axes [11]. Loss-of-function mutations in the Nodal
gene, including enhancer deletions, lead to a reduction of
Nodal RNA [12] and reveal that the highest level of Nodal
signaling is required during gastrulation for the induction of
the anterior primitive streak. This contains the precursors of
the mammalian equivalent of the amphibian Spemann’s
organizer, and it gives rise to the anterior endoderm, the
node, and the mesendoderm (notochord and prechordal
plate), all of which are required for subsequent patterning of
the vertebrate embryo [6]. Complementary experiments in
Xenopus embryos, where increasing amounts of Nodal RNA are
injected, show that it functions as a dose-dependent inducer
and that the highest level induces Spemann’s organizer [13].
The dynamic changes in the concentration of ligands, to elicit
different cellular responses, demand that the responding cells
have rapid turnover of the signaling-effectors and frequent
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PLoS BIOLOGYrefreshing of target gene promoters. Therefore, how TGF-b is
regulated, and particularly, how signaling is terminated in the
nucleus after gene transcription, is key in understanding cell
fate decisions and patterning in vertebrate development.
TGF-b signals bind to cognate serine/threonine kinase
receptors leading to phosphorylation and activation of the
Smad family of signal transducers. Two different Smad
signaling branches have been described. Ligands, like Activin,
Nodal, Gdf1, Vg1, and TGFb1 are transduced by the receptor-
activated Smad2 and Smad3 (Smad2/3) [14,15]. The phos-
phorylated form of Smads (phospho-Smads [P-Smads]) com-
plex with Smad4 and together translocate into the nucleus,
where they function as transcription factors in association
with DNA-binding partners such as FoxH1, Mixer, Jun/Fos,
Runx, ATF3, and E2F4/5, etc., which provide target gene
speciﬁcity [15]. In the mouse, loss-of-function mutations
affecting core components of the Nodal signal transduction
pathway give patterning and cell fate defects similar to that of
Nodal itself [16–20].
Extracellular cofactors [21], antagonists [22,23], and pro-
teases [24,25] have been shown to regulate Nodal activity
during mouse development. However, little is known about
the role of intracellular regulation in cells receiving Nodal.
Intracellular regulators of the pathway include negative
regulators such as inhibitory Smads (Smad6/7) that block
TGF-b signaling by competing with Smads for association
with the receptors or by targeting receptors for ubiquitin-
mediated degradation [26–28]; in the nucleus, Ski and SnoN
incorporate in the Smad DNA-binding complex to prevent
them from binding to the transcriptional coactivator p300/
CBP and repress transcription by recruiting histone deace-
tylase [29,30]. More recently, a phosphatase, PPM1A/PP2Ca,
has been identiﬁed and is shown to de-phosphorylate P-
Smad2/3 [31] and abrogate their signaling activity. Further-
more, proteasome-mediated degradation of ubiquitin-modi-
ﬁed core components of the TGF-b signaling cascade has
been shown to play a major role in controlling signaling
output [32]. Poly-ubiquitination and proteasome-dependent
degradation of proteins is one of the most prominent
turnover mechanisms in the cell. Ubiquitination of protein
substrates involves a cascade of enzymatic reactions. E3
ubiquitin ligases are the critical components responsible for
the recognition of speciﬁc substrates for ubiquitination [33].
They are generally classiﬁed into the HECT- and RING-
domain classes and exhibit substrate speciﬁcity [34,35].
Several ubiquitin ligases are known to reduce signaling by
mediating the degradation of individual components of the
pathway [28,36]. However, ligases that terminate signaling by
degrading activated Smads (P-Smads) have not been identi-
ﬁed.
One of the important unanswered questions is how long
the activated Smads transcribe target genes and how the
promoters are refreshed to allow rapid intracellular re-
sponses to dynamic changes in concentration of ligands. Both
de-phosphorylation of P-Smads followed by cytoplasmic
recycling [37] and proteasome-mediated degradation of P-
Smads have been proposed to terminate signaling in the
nucleus [38]. However, there was no explanation for how
‘‘used’’ versus ‘‘unused’’ activated effectors could be distin-
guished by these mechanisms. An obvious mechanism to limit
the time that an effector works is to link its turnover with its
ability to drive transcription.
We have shown previously that Arkadia, a nuclear RING-
domain ubiquitin ligase, enhances Nodal signaling and is
essential for the induction of the organizer/node [39,40]. In
somatic tumor cell lines, Arkadia has been shown to enhance
TGF-b signaling by ubiquitin-mediated degradation of
Smad6/7 [41,42]. However, we show here that Arkadia
functions by a different mechanism in embryonic cells.
Speciﬁcally, we ﬁnd that Arkadia directly ubiquitinates and
degrades P-Smad2/3 and that this is coupled with their high
activity. The link between activity and degradation provides a
mechanism to ensure that only ‘‘used’’ P-Smad2/3 effectors
are degraded and that signaling is terminated at the end of
the cascade and not before. Therefore, Arkadia can account
for rapid resetting of actively transcribed promoters, forcing
transcription to rely only on fresh P-Smads and allowing cells
to respond to dynamic changes in signaling. Similar
mechanisms may operate in other signaling pathways in
development to achieve peak efﬁciency and dynamic re-
sponses of cells during development.
Results
Arkadia Enhances Signaling in All Major Nodal-Dependent
Developmental Events
The phenotype of Arkadia /  embryos consists of loss of
anterior primitive streak derivatives (node, notochord,
prechordal plate, and anterior deﬁnitive endoderm [ADE]/
foregut) leading to anterior patterning defects including head
truncations [39,40]. We have shown previously that while
Arkadia or Nodal heterozygous (þ/ ) mice are normal, a small
number of double heterozygotes for Arkadia and Nodal
recapitulate the Arkadia /  phenotype [39,40]. This suggested
a functional interaction between Arkadia and Nodal. To
investigate the extent of Arkadia’s role in Nodal signaling,
and in additional Nodal-dependent developmental events, we
generated Arkadia / embryos with only one wild-type copy of
the Nodal gene (Akd / , Nodalþ/ ). The majority of Akd / ,
Nodalþ/  embryos that were analyzed (n ¼ 19/33) exhibited
phenotypes never observed in Arkadia /  embryos. Using
whole mount in situ hybridization, we performed marker
Author Summary
In development, cells respond to secreted signals (called morph-
ogens) by turning on or off sets of target genes. How does gene
activity adjust quickly in response to rapidly changing extracellular
signals? This should require efficient removal of old/used signaling
effectors (signal-activated transcription factors) from the promoters
of target genes to allow new ones to assume control. We previously
discovered Arkadia, an E3 ubiquitin ligase, and showed that it is an
essential factor for normal development. (Ubiquitin ligases trigger
the addition of ubiquitin residues to proteins, typically marking
them for degradation.) Here, we show that Arkadia is required for
high activity of the major signaling pathway, TGF-b/Nodal. Arkadia
has a dual role to degrade Smads, the TGF-b signaling effectors, and
enhance their transcriptional activity. This coupling of degradation
with activation provides a mechanism to ensure that only effectors
‘‘in use’’ are degraded, allowing the new ones to proceed. It is
possible that very similar mechanisms operate in other pathways to
establish dynamic regulation and efficient signaling, while their
failure may be associated with developmental abnormalities and
disease, including cancer.
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Smad2 Activity Linked to Ubiquitinationanalysis to deﬁne whether these phenotypes are Nodal-
dependent (Figure 1).
Before gastrulation, Nodal signaling is responsible for
anterior-posterior axis speciﬁcation via the induction of the
anterior visceral endoderm (AVE) domain at the distal tip of
the mouse embryo and its migration to the prospective
anterior [2,43]. Expression analysis of the AVE markers Hex
[44] and Cerl [45] demonstrates that the Arkadia /  embryos
are always able to induce an AVE, which correctly migrates to
the prospective anterior of the embryo (compare Figure 1A
and 1D to 1B and 1E), while the primitive streak marker
Brachyury is normally expressed posteriorly (Figure 1A and
1B). However, Akd / , Nodalþ/  embryos have incomplete
AVE-speciﬁc gene expression, as they are rarely able to
induce an AVE (one out of seven) that expresses Hex (none
out of two; Figure 1C), Cerl (one out of three; Figure 1F), or
Lefty1 (none out of two; unpublished data). Furthermore, in
the Akd / , Nodalþ/  embryos, the Cerl-expressing embryo
AVE domain remains distal (Figure 1F) and the Brachyury
domain remains proximal (Figure 1C), indicating that when
the AVE is induced it cannot migrate to the anterior. In
addition, more than 50% of the Akd / , Nodalþ/  embryos
examined at mid-streak stage have a constriction between the
embryonic and extraembryonic compartments. This pheno-
type, which is not observed in Arkadia /  embryos, is thought
to be due to a failure of the AVE to migrate and deﬁne the
anterior-posterior axis, leading to failure of primitive streak
elongation and mesoderm formation along the embryonic-
extraembryonic boundary [46]. These new phenotypes in
Arkadia /  embryos carrying only one Nodal wild-type allele
indicates that Arkadia is also involved in AVE formation and
suggests that it enhances Nodal signaling at pre-gastrulation
stages.
During gastrulation, Nodal is responsible for the formation
and patterning of endoderm and mesoderm. Cardiac meso-
derm is considered an anterior mesodermal tissue [47], and
Arkadia /  embryos form heart [39]. In contrast, all Akd / ,
Nodalþ/ embryos fail to form morphologically visible heart (n
¼4; Figure 1L), as it is also shown by loss of Nkx2.5 expression;
one of the earliest markers of myocardial differentiation [48]
(Figure 1G 1I), Shh expression (Figure 1J) marks the
mesendoderm, the midline of the neural tube (ﬂoor plate),
and the gut endoderm [49]. In Arkadia /  embryos, Shh
expression is reduced [39] due to the absence of mesendo-
derm and foregut, but it is present in the midgut and hindgut
(Figure 1K). Akd / , Nodalþ/ embryos, however, have a severe
reduction in Shh expression indicating not only loss of
mesendoderm but also of all endoderm (n ¼ 2; Figure 1L), as
conﬁrmed by histological analysis (unpublished data). These
new phenotypes seen in Arkadia / embryos carrying only one
Nodal wild-type allele indicate that during gastrulation,
Arkadia is involved in the formation of the entire endoderm
Figure 1. Arkadia Facilitates All Major Nodal-Dependent Developmental Events
(A–F) In situ hybridization on 6.5 dpc embryos (mid- to late-streak stage) shown as lateral views with anterior to the left and posterior to the right, with
probes (A–C), Hex and Brachyury; (D–F), Cer-l. In (C), Akd /  Nodalþ/  embryo showing lack of elongation and proximal positioning of the Brachyury–
expressing primitive streak, as well as loss of Hex expression indicating absence of AVE. (E) An Akd / embryo with normal Cer-l expression in the AVE
but no Cer-l expressing ADE. (F) An Akd / , Nodalþ/  embryo showing a distal Cer-l-expressing domain indicating lack of AVE migration (three other
embryos do not express Cer-l, not shown). Red arrowheads point to a constriction between extraembryonic and embryonic regions indicating
incomplete anterior-posterior axis specification.
(G–I) Nkx2.5 probe on four-somite stage, 8.5 dpc embryo showing expression in the cardiac precursor tissue in the wild-type (G) and Akd / (H), but not
in the Akd / , Nodalþ/  embryo (I).
(J–L) Shh probe on 12-somite stage embryos 9.5 dpc viewed from the ventral side with anterior toward the top. In the Akd / Nodalþ/ embryo (L), note
the reduction of Shh expression, the increased severity of the anterior truncation, and the absence of a morphologically distinguishable heart tube. PS,
primitive streak; T, Brachyury; CP, cardiac precursors; HF, head folds; NC, notochord; GE, gut endoderm. Bars, 0.1 mm.
doi:10.1371/journal.pbio.0050067.g001
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Smad2 Activity Linked to Ubiquitinationand anterior mesoderm and suggest that this is mediated by
its ability to enhance Nodal. As Arkadia facilitates Nodal
signaling broadly, before and during gastrulation, it is likely
to be a regular partner factor of the Nodal signal trans-
duction pathway.
Arkadia Acts Downstream of the Receptors and
Destabilizes the Phosphorylated Forms of Smad2/3
To ﬁnd at what position within the Nodal signaling cascade
Arkadia functions, we compared the level of the receptor-
activated (phosphorylated) signaling effector P-Smad2 in
embryos and embryonic stem (ES) cells by Western blotting
(Figure 2). We examined 20 wild-type and 20 Arkadia / 
embryos at 8.5 days post-coitum (dpc) (Figure 2A and
unpublished data) and three wild-type and three Arkadia / 
blastocyst-derived ES cell lines (Figure 2G). We found that
while the total levels of Smad2 protein remain the same, P-
Smad2 was always at least two times higher in all Arkadia / 
embryos and ES cells compared to the wild-type samples.
Similarly, the other Nodal signaling effector P-Smad3 was
found to be elevated in Arkadia / ES cell lines (Figure S1).
Therefore, in embryonic cells, P-Smad2/3 are more abundant
in the absence of Arkadia than in its presence. As the
phosphorylation of Smad2/3 depends on the kinase activity of
the ligand-activated receptors, the data suggest that in the
absence of Arkadia the receptors are more active or that P-
Smad2/3 are more stable after their phosphorylation.
We examined the activity of the receptors by stimulating
Arkadia /  and wild-type ES cells with Activin A ligand
(Activin) and comparing Smad2 phosphorylation over time
(Figure 2B–2D). Although Arkadia / cells start with higher
basal levels of P-Smad2 compared to wild-type, Smad2
phosphorylation peaks 1 h after Activin addition in all ES
cell lines (Figure 2B–2D), indicating normal receptor kinase
activity in the presence or absence of Arkadia. Interestingly,
after peak stimulation in wild-type ES cells, P-Smad2
decreases to basal levels within 2 h (Figure 2B–2D), but in
Arkadia /  ES cells P-Smad2 is maintained at peak levels
(.90%) for at least 6 more h (Figure 2B). The data suggest
that after receptor phosphorylation, Smad2 is more stable or
maintains the phosphorylation longer in the absence of
Arkadia. The total Smad2 levels do not change during the
course of the experiment, indicating that the increased
stability is associated with only the phosphorylated fraction
(Figure 2C and 2D). To examine the possibility that other
factors, such as a receptor inhibitor, is induced speciﬁcally in
wild-type cells causing reduction of Smad2 phosphorulation,
we repeated the above experiment in the presence of a
protein synthesis inhibitor (cycloheximide). The decay of P-
Smad2 was found, as before, to be slower in Arkadia /  cells
(Figure S2), suggesting that differences in protein stability
rather than synthesis account for the increase in P-Smad2
levels.
To exclude the possibility that the receptors generate the
differences in P-Smad2 levels, we blocked all the TGF-b
receptors with the serine/threonine kinase inhibitor, H7
(Figure 2E and 2F) or used SB431542 selective inhibitor of Alk
receptors (SB), which blocks the receptors that speciﬁcally
phosphorylate Smad2/3 (Figure S1A). We found that in wild-
type cells treated with two different concentrations (5 or 25
lM of H7), P-Smad2 levels declined 40% and 60%,
respectively, within 30 min and they diminished to 30% after
90 min. In Arkadia /  ES cells, however, even after 90 min,
with the highest amount of inhibitor, P-Smad2 levels were not
signiﬁcantly changed (Figure 2F). The data indicate that the
receptors are not responsible for generating the increase of
P-Smad2 in Arkadia /  cells and suggest that this is caused by
P-Smad2 stabilization. The total Smad2 protein levels do not
change during the course of the experiment (Figure 2E), but
as the fraction of P-Smad2 is most likely small, differences
within this fraction may not be visible when the total levels
are examined. All of the above experiments were reprodu-
cible in three different Arkadia /  ES cell lines (unpublished
data) and the same results were obtained for the other Nodal/
Activin effector, P-Smad3 (Figure S1B). Collectively, the data
suggest that Arkadia acts downstream of the receptors and
destabilizes the phosphorylated forms of Smad2/3.
Smad4/P-Smad2/3 Are Nuclear in the Absence of Arkadia
P-Smad2/3 complex with Smad4 and translocate to the
nucleus where they activate target genes and are subjected to
different mechanisms of turnover and signaling termination
such as ubiquitination/proteasome-mediated degradation
[38] or de-phosphorylation [31] and nuclear export [50,51].
Cytoplasmic retention of P-Smad2/3 can result in both
inability to activate target genes and increased stability. As
in the absence of Arkadia, P-Smad2/3 are more stable and less
transcriptionally efﬁcient; it is possible that they are
cytoplasmic and Arkadia regulates their nuclear localization.
We therefore examined in three different wild-type and three
Arkadia /  ES cell lines the localization of P-Smads using
Western blots of nuclear and cytoplasmic fractions (Figure
2G) or by immunoﬂuorescence (Figure 2H) with antibodies
against P-Smad2 or Smad2/3. We did not ﬁnd evidence that P-
Smads are cytoplasmic in the absence of Arkadia. On the
contrary, the Western blots revealed that P-Smad2 accumu-
lates in the nucleus of Arkadia / cells. Furthermore, as P-
Smad2/3 complex with Smad4 to translocate to the nucleus
[15], an increase of Smad4 in the nucleus of Arkadia /  ES
cells was observed (Figure 2G). Therefore, we conclude that
Arkadia destabilizes P-Smad2/3 without affecting Smad4
complex formation and nuclear localization. Furthermore,
as Arkadia is nuclear, the data suggest that Arkadia regulates
P-Smad2/3 stability in the nucleus.
Arkadia Interacts Directly with P-Smad2/3
Arkadia is an E3 ubiquitin ligase and could be destabilizing
P-Smad2/3 directly by poly-ubiquitinating them, leading to
their proteasome-dependent degradation. To test this hy-
pothesis, we examined whether Arkadia interacts speciﬁcally
with phosphorylated Smads. We used HEK293T (293T) cells
stably expressing moderate levels of full-length Arkadia,
tagged either with Flag on the N-terminus and Myc on the
C-terminus, or with green ﬂuorescent protein (GFP) fused to
the N-terminus (GAkd). We performed immunoprecipitation
(IP) with anti-Flag (Figure 3A and 3B), -Myc, or -GFP
(unpublished data) antibodies and Western blotted with
anti-P-Smad2, -Smad2 (Figure 3A), or -P-Smad3 (Figure 3B).
The results show that with Activin stimulation, Arkadia coIPs
with the phosphorylated endogenous Smad2 (Figure 3A) and
Smad3 (Figure 3B). However, when the cells are treated with
the SB receptor inhibitor, which eliminates Smad2/3 phos-
phorylation, Arkadia does not coIP unphosphorylated
Smad2/3 (Figure 3A and unpublished data). Furthermore,
PLoS Biology | www.plosbiology.org March 2007 | Volume 5 | Issue 3 | e67 0589
Smad2 Activity Linked to UbiquitinationPLoS Biology | www.plosbiology.org March 2007 | Volume 5 | Issue 3 | e67 0590
Smad2 Activity Linked to Ubiquitinationwe examined the interaction of Arkadia with other phos-
phorylated Smads (Smad1/5/8; Figure S3A) or with Smad4
(unpublished data) and found no evidence of interaction. We
therefore conclude that Arkadia interacts speciﬁcally with the
phosphorylated forms of Smad2/3.
To test how direct this interaction is, we performed the IP
in vitro (Figure 3C) using in vitro transcribed/translated
(recombinant) Arkadia protein labeled with S
35 and phos-
phorylated Flag-tagged Smad2 isolated by IP (Figure S3B)
from 293T cells stimulated with constitutive active Alk4
(Alk4*). The data show that phosphorylated ﬂag-Smad2
protein can IP recombinant full-length Arkadia but not the
N-terminal portion (1–510 amino acids [aa]), or the luciferase
control (Figure 3C). The data suggest that Arkadia interacts
directly with P-Smad2/3 via a C-terminal domain.
Arkadia is a 989-aa protein and its C-terminal half (516–
989 aa) contains a highly conserved domain of 100 aa (889–
989 aa), which includes the RING-ubiquitin ligase activity-
domain at the C-terminal region (947–965 aa), a nuclear
localization signal (NLS) (903–909 aa), and a conserved
domain (889–903 aa), termed here NRG, of unknown function
(Figure S3C). To understand the interaction of Arkadia with
P-Smad2/3, we mapped further the responsible domain. We
used transient transfections of 293T cells to test the ability of
various deletions of Arkadia (all GFP-tagged; Figure 3D) to IP
P-Smad2/3. The data show that the last 100 aa of Arkadia
containing the NRG, the NLS, and the RING (G-NRG-RING,
889–989 aa; Figure 3D) are sufﬁcient for the interaction
(Figure 3D). Deletion of the C-terminal end of Arkadia
(GAkdR*) that eliminates one of the Zinc-binding ﬁngers of
the RING domain (965–989 aa) does not affect the interaction
with P-Smad2/3 (Figure 3F). However, deletion of the NRG
completely abrogates the interaction with P-Smad2 (Figure
3E). To conﬁrm that the NRG domain is necessary for the
interaction with P-Smad2/3 within the context of the full-
length Arkadia protein, we generated an internal partial
deletion of only the ﬁrst eight residues of the NRG
(GAkdNRG*) and showed that it diminishes the interaction
with P-Smad2/3 (Figure 3F). As judged by ﬂuorescence from
the GFP tag, all of the above mutant Arkadia proteins are
localized in the nucleus and are expressed at comparable
levels to full-length Arkadia (Figure S4), indicating that loss of
the interaction of the various Arkadia deletion constructs is
not due to instability or differential localization. Collectively,
the above data indicate that Arkadia interacts directly with P-
Smad2/3 via its 100-aa C-terminal portion and that within this
domain, a 14-aa NRG motif is essential for this interaction. As
the 293T cells that we used for the IPs do not express FoxH1
(unpublished data), one of the major P-Smad2/3 transcription
partners in early embryogenesis, we conclude that the
interaction of Arkadia with P-Smad2/3 may not depend on
a particular partner.
P-Smad2/3 Are Substrates of Arkadia Ubiquitination
As P-Smad2/3 interact with Arkadia, it is possible that they
are substrates of Arkadia ubiquitination. To address this, we
examined the ubiquitination status of P-Smad2 in the
presence or absence of Arkadia expression. We used
Arkadia /  mouse embryonic ﬁbroblasts lines (MEFs) to
exclude any endogenous Arkadia activity and introduced
Flag-Smad2 and Alk4* to obtain phosphorylated Flag-Smad2,
in the presence of full-length or mutant forms of Arkadia.
Western blot analysis of the IPs with anti-P-Smad2 antibodies
showed the existence of higher molecular weight forms of P-
Smad2 associated speciﬁcally with the presence of full-length
Arkadia (Figures 4A and 4B and S4) suggesting poly-
ubiquitination. Probing with ubiquitin antibodies conﬁrmed
that these modiﬁcations contain ubiquitin chains (Figures 4A
and 4B and S4). Furthermore, these blots show that P-Smad2
is not ubiquitinated in the presence of mutant Arkadia
proteins lacking either ubiquitin ligase activity (GAkdR*) or
the P-Smad2 interaction domain (GAkdNRG*; Figure 4A and
4B). Therefore, Arkadia ubiquitinates P-Smad2 in vivo, and
this depends on both its ubiquitin ligase activity and the P-
Smad2/3 interaction domain, suggesting that Arkadia ubiq-
uitinates them directly.
To verify that P-Smad2/3 ubiquitination is directly depend-
ent on Arkadia, we performed the assay in vitro by adding all
the components of ubiquitination separately along with
recombinant full-length Arkadia, the C-terminal part of
Arkadia containing the RING and the NRG, or N-terminal
Arkadia. In this reaction we added the phosphorylated Flag-
Smad2 obtained by IP as shown before (Figure S3B), and
examined by Western blot, with anti-P-Smad2 antibody,
whether or not it becomes modiﬁed by the ubiquitination
reaction. We found that the full-length and C-terminal
Arkadia are capable of poly-ubiquitinating in vitro Flag-P-
Smad2, only when all the ubiquitination components were
present, while the N-terminal Arkadia does not (Figures 4C
and S5B). In addition, the Flag-P-Smad2 substrate does not
become ubiquitinated without the addition of recombinant
Arkadia, indicating that the IP is not contaminated with
Figure 2. In the Absence of Arkadia, P-Smad2 Is More Stable and Correctly Localized in the Nucleus
(A) Western blot of 8.5 dpc wild-type and Akd /  embryo extracts. Each lane contains total protein extracts from three embryos. Note that P-Smad2
levels are at least 2-fold higher in mutants than in wild-type.
(B and C) Western blot of extracts from Akd / and wild-type ES cells cultured with Activin for different intervals (in minutes (’) and hours (h). Note that
P-Smad2 is more stable in mutant than in wild-type cells. Loading control: PCNA, proliferation cell nuclear antigen.
(D) Densitometry analysis of the bands on the blots in (C) showing the trend in P-Smad2 levels normalized against Smad2 where Akd / ES cells treated
with Activin for 45 min is taken as 100%.
(E) Western blot analysis showing P-Smad2 and Smad2 levels in ES cells stimulated with Activin for 1 h (1 h Act) and subsequently treated for different
time points with H7 inhibitor as indicated.
(F) Densitometry analysis of the blots in (E) showing the trend in P-Smad2 levels normalized against Smad2 where Akd / and wild-type ES cells treated
with Activin for 1 h are represented as 100%.
(G) Western blot showing P-Smad2 and Smad4 protein distribution in cytoplasmic and nuclear fractions of three different wild-type and Akd / ES cell
lines as indicated. 30 lg of each protein sample was loaded for analysis. Histone H3, a nuclear protein, was used as a control for fractionation. C,
cytoplasmic; N, nuclear.
(H) Immunofluorescence with anti-P-Smad2 and anti-Smad2/3 (red) antibody on Akd / and wild-type ES cells treated with Activin A for 1.5 h prior to
fixation, indicating no difference in the localization of P-Smad2 in the absence of Arkadia. Note the nuclear accumulation of P-Smad2, Smad2/3, and
Smad4 in Akd /  cells. White bar, 12 lm. WT, wild-type.
doi:10.1371/journal.pbio.0050067.g002
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Smad2 Activity Linked to Ubiquitinationubiquitin ligases from the cells. Collectively, the data show
that P-Smad2/3 are ubiquitinated directly by Arkadia in vivo
and in vitro, and therefore, they are qualiﬁed substrates of
Arkadia ubiquitination.
Arkadia Mediates Proteasome-Dependent Degradation of
P-Smad2
Poly-ubiquitination of proteins usually leads to degrada-
tion via the proteasome [34,35]. Consistent with this, our data
show that P-Smad2/3 are unstable in the presence of Arkadia
(Figure 2), but it was unknown whether this instability is
mediated by the proteasome. To address this, we transfected
Arkadia /  MEFs with full-length Arkadia or Arkadia lacking
ubiquitin ligase activity under ligand stimulation and
examined with an anti-P-Smad2 antibody the stability of
transfected P-Flag-Smad2 (Figure 4D) or endogenous P-
Smad2 (Figure 4E) in the presence or absence of MG132
proteasome inhibitor. We found that P-Smad2 levels are
Figure 3. Arkadia Interacts Directly with P-Smad2/3 and This Requires the NRG Domain
(A and B) IP with anti-Flag antibody from 293T cells stably expressing Flag-tagged Arkadia (Flag-Akd). Cells were cultured with Activin A (A) or SB and
Western blotted with anti-P-Smad2 (A) or anti-P-Smad3 antibody (B). Note that Flag-Akd coIPs endogenous P-Smad2 (A) and P-Smad3 (B) in Activin and
not in the SB-treated sample. Western blotting of IPs with anti-Smad2 antibody reveals this interaction to be specific to the phosphorylated form of
Smad2 (A). The band in the total tissue cell lysates (TCL) and supernatants (SN) in SB-treated samples may correspond to P-Smad1 that does not coIP
with Flag-Arkadia (B). Compare the intensity of the band in the TCL and SN to see the depletion of P-Smad3 after IP.
(C) Autoradiograph showing in vitro transcribed/translated
35S-labeled full-length Arkadia (Akd), N-terminal portion (N-Akd), and luciferase (Luc) protein
input. Flag-P-Smad2 (Figure S3B) attached to agarose beads was able to pull down specifically Akd and not N-Akd or Luc.
(D) Map of Arkadia deletion constructs fused in frame with GFP on the N-terminus except for N-Akd. The numbers correspond to amino acid positions.
NRG domain, dark gray; NLS, light gray; RING, black (see the amino acid sequence in Figure S3C). GAkdNRG* contains a partial internal deletion of the
NRG domain (aa D 889–895).
(E and F) IP with anti-GFP antibody from 293T cells transfected with GFP or GFP-tagged Arkadia constructs as indicated, along with Alk4* and either
Flag-Smad2 (E) or myc-Smad3 (F) and Western blotted (WB) with antibodies as indicated. P-Smad2 protein is shown to coIP with the G-NRG-RING and
not with other shorter forms missing the NRG domain. P-Smad3 protein is shown to coIP with full-length Arkadia (GAkd) and a RING domain deletion
(GAkdR*). Note the presence of ladder and smear in GFP-tagged Arkadias including the G-NRG-RING, indicating that these proteins are unstable and
heavily modified (including poly-ubiquitin chains; unpublished data).
doi:10.1371/journal.pbio.0050067.g003
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Smad2 Activity Linked to UbiquitinationFigure 4. Arkadia Ubiquitinates P-Smad2 and Mediates Its Degradation via the Proteasome
(A and B) IP with anti-Flag antibody from Akd / MEFs transiently transfected with various plasmids as indicated, and Western blotted (WB) with anti-P-
Smad2, anti-HA, or anti-ubiquitin antibodies. Note the presence of higher molecular weight P-Smad2 corresponding to protein modifications, including
ubiquitin chains as shown by the presence of HA-ubiquitin tags (A) or ubiquitin (B). These are present only in cells transfected with full-length Arkadia
and not with GFP (A and B) or mutant forms GAkdR* (A) and GAkdNRG* (B), which disrupt the ubiquitin ligase activity and the interaction with P-Smad2,
respectively.
(C) In vitro poly-ubiquitinated P-Smad2 (bracket) was detected by Western blotting with anti-P-Smad2 antibody. Note the presence of high molecular
weight species only in the reactions containing in vitro transcribed/translated full-length (Akd) or the C-Akd (aa 510–989) Arkadia proteins (see WB with
anti-ubiquitin in Figure S5A). Retic., Reticulocyte extract; E1 þ E2, ubiquitination enzymes; GST-Ub, GST-tagged ubiquitin.
(D and E) Nuclear extracts from Akd /  MEFs transfected with either GAkd, GFP, or GAkdR* plasmids alone (E) or with Flag-Smad2 and Alk4* (D) and
treated with either MG132 (þ;3 0lM) or DMSO ( ) for 4 h prior to lysis, and Western blotted with anti-P-Smad2 and either anti-PCNA (D) or anti-Tubulin
(E) antibodies for loading controls. P-Smad2 protein levels decrease specifically in cells expressing Arkadia, and this does not occur when the
proteasome is inhibited or when the RING domain is mutated (GAkdR*), indicating that the degradation is mediated via the proteasome and the
ubiquitin ligase activity of Arkadia. (E) Graphical representation of relative endogenous P-Smad2 levels normalized against the housekeeping gene
Tubulin shows approximately a 2.5-fold reduction of P-Smad2 in Arkadia-expressing MEFs in the presence of DMSO when compared to MG132. GFP-
and GAkdR*-expressing MEF samples do not show any differences.
(F) Western blots (WB) with anti-P-Smad2 and anti-Tubulin antibodies showing the rate of P-Smad2 degradation in wild-type and Akd / ES cells in the
presence of MG132 or DMSO control. After initial stimulation with Activin (0*), P-Smad2 is rapidly degraded in wild-type ES cells but not in Akd / . This
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and that MG132 can inhibit this. Therefore, Arkadia, via its
ubiquitin ligase activity, is sufﬁcient to induce P-Smad2
proteasome-dependent degradation.
In the above experiments, the degradation of P-Smad2 was
achieved by the transfection of exogenous Arkadia in  / 
MEFs. To examine whether endogenous Arkadia is necessary
for proteasome-dependent degradation of P-Smad2, we
compared its decay in Arkadia /  and wild-type ES cells in
the presence or absence of MG132. For this we ﬁrst
stimulated the ES cells with Activin (1 h), then added SB
inhibitor to prevent further phosphorylation of Smad2 and
examined its decay at different time points (Figure 4F). We
found that MG132 protects P-Smad2 in wild-type ES cells but
has very little effect in Arkadia /  (Figure 4F). Therefore,
Arkadia, by direct poly-ubiquitination, most likely mediates
degradation of P-Smad2 by the proteasome.
Arkadia Is Necessary and Sufficient to Enhance P-Smad2/3
Transcriptional Activity
We showed above that loss of Arkadia leads to the
stabilization and nuclear accumulation of P-Smad2/3. But
do these higher levels correspond to an increase in target
gene transcription? Analysis of Arkadia /  and compound
Arkadia / , Nodalþ/  embryos showed that Nodal signaling is
defective (Figure 1 and [39,40]) suggesting that Smad2/3 target
gene transcription is compromised. We examined the tran-
scriptional activity of P-Smad2/3 in three Arkadia /  and
three wild-type ES cell lines. To estimate the relative levels of
P-Smad2/3 transcriptional activity, we used two different
target gene luciferase reporters, 0.9-P1, (hereafter termed
Pitx2-luc) regulated by P-Smad2/3 and its partner factor
FoxH1, and 9xCAGA–luc, a Smad3 speciﬁc reporter [52,53].
Although the Arkadia /  ES cell lines always have a higher
amount of P-Smad2 protein compared to wild-type, they have
on average 30% (Figure 5A) lower luciferase from the wild-
type cell line with the lowest activity (WT 3 designated as
reference ¼ zero). Stimulation with Activin did not change
signiﬁcantly the luciferase reporter expression (unpublished
data); indicating that under standard culture conditions ES
cells exhibit ligand-saturated signaling (autocrine signaling).
In addition, real-time PCR showed that the expression of the
endogenous Nodal gene, which like the Pitx2-luc luciferase
reporter is regulated by FoxH1/Smad2/3 binding sites (known
as ASE) [12], is reduced by about 70% in Arkadia /  ES cells
(Figure 5B). Together, these observations suggest that Arkadia
is necessary for efﬁcient target gene expression and suggest
that in its absence, the stable and high levels of P-Smad2/3 are
hypoactive or prevented from activating their target genes.
Therefore, although Arkadia degrades P-Smad2/3, it is
necessary for efﬁcient P-Smad2/3 transcriptional activity.
To address whether Arkadia is sufﬁcient to activate P-
Smad2/3, we performed gain-of-function experiments in ES
cells. We introduced full-length Arkadia (GFP-tagged; GAkd)
in three  /  ES cell lines and showed that it enhances the
expression of the luciferase reporters on average 100%
(Figure 5C) and 230% (Figure 5D) above the level of a GFP-
expressing plasmid. Interestingly, in wild-type ES cells,
Arkadia does not signiﬁcantly change the reporter activity
(Figure 5C and 5D) even after Activin stimulation (unpub-
lished data). This indicates that endogenous Arkadia is
adequate to activate all P-Smad2/3 generated by the receptors.
Together, these results suggest that Arkadia is necessary and
sufﬁcient to enhance P-Smad2/3 target gene transcription.
Arkadia Enhances and Degrades P-Smad2/3 via the Same
Domains
According to the above data, Arkadia has two functions: to
destabilize P-Smad2/3 and enhance their activity. As it is
possible that different domains mediate the two opposing
functions, we used the / ES cell functional assay to identify
domains that are essential for Arkadia to enhance reporter
activity. We found that Arkadia constructs with ubiquitin
ligase domain mutations (GAkdR* and GAkdR2*) or Arkadia
without the P-Smad2/3 interaction domain (NRG deletion,
GAkdNRG) fail to enhance (Figure 5E); suggesting that like
the degradation of P-Smad2/3, activation also requires a
direct interaction with Arkadia and its ubiquitin ligase
activity. Examination of several N-terminal deletions (Figure
3D) showed that the C-terminal half (516–989 aa) of Arkadia
is the minimum region sufﬁcient to enhance the reporter
efﬁciently (unpublished data). Furthermore, loss of the P-
Smad2/3 activation, but not the degradation properties of
Arkadia, is expected to convert it to a repressor of signaling.
However, none of the deletions and mutations of Arkadia
separated the two functions. Together, the above data suggest
that Arkadia activates and degrades P-Smad2/3 via the same
domains and that the two functions are most likely coupled.
Enhancement of P-Smad2/3 by Arkadia Occurs at the
Expense of Their Abundance
To test whether the activation of the hypoactive P-Smad2/3
by Arkadia occurs at the expense of their levels, we examined
the relationship between levels of endogenous P-Smad2 and
the degree of enhancement after expression of Arkadia in / 
ES cells. To visualize levels of endogenous P-Smad2, we
isolated by ﬂuorescence-activated cell sorting (FACS) pure
populations of cells transfected with GAkd or enzymatically
(ubiquitin ligase) inactive Arkadia (GAkdR*) or control GFP
constructs. A portion of the cells was used for luciferase
assays and the rest was used to examine endogenous P-Smad2
and total Smad2 levels in Western blots. As before, Arkadia
enhances signaling only in  /  ES cells in a ubiquitin-ligase-
dependent manner (Figure 6A); and this phenomenon was
accompanied by an 80% reduction in the level of P-Smad2
(Figure 6B), conﬁrming that activation of the hypoactive P-
Smad2 is followed by its degradation.
We performed the same experiment in wild-type ES cells
and found that overexpression of Arkadia does not change
the levels of endogenous P-Smad2 or the reporter activity
(Figure 6A and 6B). We conclude that in wild-type cells
endogenous Arkadia must be in excess and sufﬁcient to
activate all available P-Smad2/3 in the nucleus. The fact that
P-Smad2 is not eliminated and signaling is never repressed by
the overexpression of Arkadia suggests that only a fraction of
P-Smad2 interacts with and gets degraded by Arkadia, i.e.,
degradation in wild-type cells is reduced in the presence of MG132 compared to the DMSO control, indicating that it is mediated via the proteasome.
SB, SB431542; WT, wild-type.
doi:10.1371/journal.pbio.0050067.g004
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The above data conﬁrm the dual role and coexisting
functions of Arkadia, suggesting that Arkadia enhances P-
Smad2/3 activity at the expense of their levels.
Super-Activation by Arkadia in  /  ES Cells Is a Transient
Phenomenon
An interesting observation is that in  /  ES cells, Arkadia
expression not only restores the transcriptional deﬁcit but it
Figure 5. Arkadia Is Required for Efficient P-Smad2/3 Target Gene Transcription and Super-Activates Signaling in Akd /  ES Cells
(A) Relative luciferase activity from three different wild-type and three different Akd / ES cell lines transfected with the Pitx2-luc reporter. All values are
expressed as a percentage relative to wild-type cell line 3 (3) represented as 0%. Akd /  ES cell lines have lower activity compared to wild-type,
indicative of reduced target gene expression. Average differences (Av) between wild-type and Akd /  ES cells are shown.
(B) Nodal real-time PCR performed on two different wild-type and Akd / ES cell lines (1 and 2). The abundance of endogenous Nodal transcripts was
quantified and normalized against two different housekeeping control genes, YWHAZ and GAPDH, in quadruplicate reactions (n ¼ 4 for each primer
pair). Both Akd /  ES cell lines show reduced levels of endogenous Nodal, a known target gene of P-Smad2/FoxHI compared to wild-type.
(C) Percentage change in Nodal/TGF-b signaling as quantified by Pitx2-luc assays upon transient transfection of GFP or GAkd plasmids in three wild-type
and three Akd /  ES cell lines. GAkd expression doubles Pitx2-luc reporter activity in Akd /  ES cells and the enhancement is 50% higher than the
average level (Av) of wild-type ES cells (horizontal line). The values are normalized against GFP-transfected Akd /  cell line 3, which has the lowest
signaling.
(D) Percent (%) increase in luciferase activity generated by the transiently transfected Smad3 specific 9xCAGA-luc reporter in the presence of GFP- or
GAkd-expressing plasmids in Akd / and wild-type ES cells showing that Arkadia super-activates Smad3-dependent transcription. The enhancement is
100% higher than that in wild-type ES cells (horizontal line). The luciferase values are expressed relative to that of Akd /  cells transfected with GFP
taken as 0%.
(E) Super-activation is abolished when mutant Arkadias, GAkdR*, and GAkdNRG* are transfected, indicating that the enhancement requires Arkadia
ubiquitin ligase activity and an interaction with P-Smad2/3.
(F) Time course of super-activation shows that it is an early but transient phenomenon as quantified by the Pitx2-luc reporter. Relative luciferase activity
of Akd / and wild-type ES cells are expressed as percent increase over the GFP control and compared at time points (h, hours) taken after transfection
of GAkd or GFP. WT, wild-type.
doi:10.1371/journal.pbio.0050067.g005
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or 100% (Figure 5D) above the maximum level that can be
achieved in wild-type ES cells. The simplest explanation for
this phenomenon is that the extra activity most likely reﬂects
the accumulated levels of the hypoactive P-Smad2/3 that is
being simultaneously activated by the expression of Arkadia.
As this enhancement exceeds the maximum that can be
achieved in wild-type ES cells even under ligand stimulation
conditions, we termed it super-activation. According to this
hypothesis, Arkadia expression in  /  ES cells will eventually
‘‘consume’’ (activateanddegrade)theaccumulatedP-Smad2/3,
releasing their activity to produce a transient super-activation
of target genes. Subsequently, target gene transcription will be
reduced to basal levels similar to that of wild-type cells.
We tested this prediction by comparing the percentage of
enhancement by GAkd over that of the GFP control at
different time points after transfection in Arkadia / ES cells.
The results indicate that maximum super-activation occurs as
early as 9 h post-transfection and coincides with the
appearance of GFP ﬂuorescence, declines after 15–18 h, and
disappears after 30 h (Figure 5F). GFP ﬂuorescence remained
high throughout the experiment and past 48 h (unpublished
data) and does not account for the loss of super-activation at
30 h. The above data suggest that in  /  ES cells Arkadia
releases the activity of the hypoactive and stable P-Smad2/3
pool causing target gene transcription above wild-type levels
(super-activation), and as this is a transient phenomenon, it
occurs at the expense of P-Smad2/3 abundance. Therefore,
Arkadia functions by a mechanism that consumes P-Smad2/3
as it activates them.
Arkadia Is Required for Nodal Target Gene Expression in
the Embryo
All the above analysis shows that in ES cells Arkadia
functions as a coactivator of P-Smad2/3 transcription. To
address whether this also occurs in other embryonic cells and
if this is the underlying cause of the Arkadia /  phenotype in
the embryo, we examined the expression of known Smad2
target genes in Arkadia /  embryos. The FoxH1/P-Smad2
complex directly upregulates the Nodal gene and is respon-
sible for its tissue-speciﬁc expression in the visceral endo-
derm (VE) at pre-gastrulation stages [10,12,54]. Whole mount
in situ hybridization, as expected, revealed that in Arkadia / 
embryos (n ¼ 10) Nodal expression is dramatically reduced in
the epiblast and almost lost in the VE (Figure 7A and 7B).
Later in development, FoxH1/Smad2/3 regulates directly
Nodal [12], Pitx2, and Lefty2 [55,56] expression, in the left
lateral plate mesoderm (LPM). However, this expression
cannot be assessed in Arkadia /  embryos because they lack
a node and mesendoderm, which are essential for establishing
left-right asymmetry. Using tetraploid chimeras (TC), we have
previously shown that restoration of Arkadia expression in the
extraembryonic lineages is sufﬁcient to rescue the node and
notochord formation in an embryo that consists entirely of
Arkadia /  cells [39]. We therefore generated TC embryos by
injecting Arkadia /  ES cells in tetraploid wild-type blasto-
cysts. The rescue of node formation in the Arkadia /  TC
embryos is shown with the appearance of Nodal expression
around the node (Figure 7D), which is absent in Arkadia / 
embryos (Figure 7E). We used these rescued Arkadia / 
embryos to examine target gene expression in the left LPM.
In the left LPM, expression of Nodal, Lefty2, and Pitx2 is
present in wild-type (Figure 7G, 7I, and 7K) and absent in
Arkadia / embryos (Figure 7F), while in the TC embryos (n ¼
9), Nodal and Pitx2 expression is severely reduced (Figure 7H
and 7L) and Lefty2 is undetectable (Figure 7J), indicating that
Arkadia is required for Nodal target gene expression in the
Figure 6. Activation of P-Smad2 Occurs at the Expense of Its Abundance
Wild-type and Akd /  ES cells transiently transfected with the Ptx2-luc
reporter along with GFP, GAkd, or GAkdR* plasmids and isolated by FACS
for GFP expression. Half of the cells were analyzed for luciferase activity
(A) and the other half were Western blotted with anti-P-Smad2, -Smad2,
and -PCNA (loading control) antibodies (B). Note that expression of full-
length Arkadia results in super-activation and a reduction of around 80%
of P-Smad2, only in Akd /  ES cells, which have an accumulation of P-
Smad2 (compare P-Smad2/Smad2 ratio). The phosphorylated Smad2
fraction is small as the ES cells are not stimulated (i.e., transfected with
Alk4*), and therefore, the degradation of P-Smad2 is not reflected in the
total level of Smad2. The graph represents P-Smad2 levels normalized
against PCNA.
doi:10.1371/journal.pbio.0050067.g006
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Smad2 Activity Linked to UbiquitinationFigure 7. Arkadia Regulates Nodal Target Gene Expression and Phenocopies Smad2 in Development
In situ hybridization with Nodal probe on 6.5 dpc (A and B) and 8.5 dpc (C–H) embryos; (C–H) embryos are shown as ventral views with anterior to the
top and left toward the right; (A, C, and G) wild-type (þ/þ); (B, E, and F) Arkadia / ( / ); and (D and H) tetraploid chimeras (TC). Compare (A) and (B) to
see reduced Nodal expression in the mutant embryo. The TC shows normal expression of Nodal around the node (D) and reduced expression in the left-
LPM (H), while the / embryo has no node or Nodal expression (E and F). Lefty2 probe on 8.5 dpc embryos (I and J) showing loss of expression in the
left-LPM in the TC; Pitx2 (K and L) on 9.5 dpc embryos showing reduction of expression in the TC; and Hex (M and N) on 8.5 dpc showing loss of
expression in the foregut pocket of the TC. Heart-level sections from 9.5 dpc (O) and 8.5 dpc (P) mosaic embryos (chimeras) stained for b-galactosidase
activity (blue). Note selective contribution of wild-type cells in the foregut. Black arrowheads point at the visceral endoderm; black arrow, points at the
node; red dots indicate the left-LPM; red arrows point at the head folds; red arrowheads indicate the definitive endoderm at the level of the foregut.
Bars, 0.1 mm.
doi:10.1371/journal.pbio.0050067.g007
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Smad2 Activity Linked to UbiquitinationLPM. Furthermore, the expression of Nodal in the node of the
TC embryos is not reduced (compare Figure 7C and 7D) and
is consistent with previous ﬁndings that this expression does
not depend on Smad2/3 [12,57]. This conﬁrms that Arkadia is
required speciﬁcally for the expression of Smad2/3 target
genes in vivo. Therefore, in the absence of Arkadia, Nodal
target gene expression is reduced broadly in many cells and
tissues throughout early embryogenesis, before and during
gastrulation, and can account for the developmental defects
observed in the  /  embryos. In addition, the effect of
Arkadia on Nodal gene expression can explain its non-cell
autonomous functions in the Arkadia /  TC embryos where
wild-type VE (expressing Nodal) can rescue node formation,
and those reported in the literature for Xenopus assays [39,40].
Arkadia Phenocopies Smad2 and Is Required for Foregut
and Prechordal Plate Formation
According to the biochemical and functional data in ES
cells, Arkadia interacts with P-Smad2, and this interaction is
essential for the full expression of target genes. It is therefore
expected that Arkadia /  embryos and ES cells will have
similar defects and exhibit the same phenotypes with those of
Smad2 /  cells. The phenotype of mice with conditional
FoxH1 or Smad2 deletion exclusively in the epiblast shows that
they cannot form ADE/future foregut or prechordal plate (the
most anterior mesendoderm). Furthermore, injection of
FoxH1 /  or Smad2 /  ES cells in wild-type blastocysts shows
that the  /  cells cannot colonize tissues such as the gut and
the prechordal plate, indicating a cell autonomous require-
ment for these factors in these chimeras (mosaic embryos)
[58,59]. It is therefore expected that Arkadia /  embryos and
ES cells will have the same defect and exhibit the same
phenotypes with those of Smad2 / cells. Expression of Hex, an
ADE/foregut marker [44] (Figure 7M and 7N) and Shh, a
prechordal plate marker (Figure S6), show that although
Arkadia / TC embryos develop node and mesendoderm, they
exhibit a deﬁcit in these tissues. Consistent with the role of
the ADE and the prechordal plate in maintaining and
patterning the head folds, we observed that the Arkadia / 
TC exhibit reduction of the head folds (Figure 7J, 7L, and 7N)
that can also account for the reduction of Pitx2 expression in
the forebrain (Figure 7L).
The requirement for Arkadia expression within the cells
that form the ADE/foregut and the prechordal plate was
addressed in mosaic chimeras generated either by injection of
wild-type ES cells into Arkadia / blastocysts (Figure 7O) or by
Arkadia /  ES cells into wild-type blastocysts (Figure 7P) [39].
In both types of chimeras, the embryo consists of a mixture of
wild-type (unstained) and Arkadia /  cells (b-galactosidase
stained) [39]. We found that mosaic chimeras (n . 100)
exhibit normal morphology, as long as wild-type cells
colonize the foregut and the prechordal plate (Figure 7O
and 7P). Therefore, like Smad2, Arkadia is required cell
autonomously for ADE/foregut and prechordal plate for-
mation. The above data show that Arkadia loss-of-function
phenocopies that of Smad2 in embryonic cells, supporting a
functional interaction between the two factors.
Discussion
An important unanswered question is how the promoters
of target genes are cleared and refreshed from transcription
factors that are activated by signal transduction pathways to
allow rapid intracellular responses to dynamic changes in the
concentration of extracellular ligands. We show here that
Arkadia terminates signaling at the level of transcription, by
linking the ubiquitination/degradation of P-Smad2/3 to their
transcriptional activity. Therefore, this mechanism enhances
transcription but limits the time that the effector works by
inducing its turnover. This represents the ﬁrst example of
coupled activation and degradation of signaling effectors, as
well as a critical role for this mechanism in development. It is
possible that very similar mechanisms operate in other
pathways to establish dynamic regulation and efﬁcient
signaling, while their failure may be associated with disease.
P-Smad2/3 Turnover
Experiments using somatic tissue culture cell lines showed
that Arkadia might enhance TGF-b signaling by degrading
the Smad6/7, which are known to inhibit Smad2/3 phosphor-
ylation mainly by mediating the degradation of the receptors
[41,42]. If this is the case, then embryos and ES cells should
have reduced levels of P-Smad2/3 in the absence of Arkadia.
Contrary to this prediction, all Arkadia /  embryos and ES
cells have at least 2-fold higher P-Smad2/3 levels compared to
wild-type. Therefore, Arkadia must enhance signaling via a
different mechanism during early development.
In vivo, in ES cells, MEFs, and embryos, loss of Arkadia
causes P-Smad2/3 stabilization and accumulation in the
nucleus and makes them resistant to proteasome degradation
(Figure 4), suggesting that Arkadia directly or indirectly is
associated with their stability and degradation. Destruction of
P-Smad2 had been shown previously to occur in the nucleus
[38], but a nuclear ubiquitin ligase that interacts speciﬁcally
with the phosphorylated form of Smad2/3, as well as the role
of proteasome-mediated turnover of P-Smads during devel-
opment, remained unknown. We present here a number of
experiments indicating that Arkadia, a nuclear E3 ubiquitin
ligase, interacts with P-Smad2/3 and directly ubiquitinates
them leading to their degradation by the proteasome. These
include IP experiments showing that Arkadia interacts
speciﬁcally with the phosphorylated forms of Smad2/3 via
the conserved NRG domain (Figure 3A and 3B), and in vitro
ubiquitination assays showing that Arkadia directly poly-
ubiquitinates P-Smad2 (Figures 4A–4C and S5). Furthermore,
introduction of Arkadia in  /  cells causes P-Smad2 poly-
ubiquitination and decreases its abundance in a proteasome-
dependent manner (Figure 4D–4E). However, as Arkadia is
nuclear, it most likely degrades nuclear P-Smads.
Signaling Termination at the End of the Cascade
One of the major questions is how effector activity is
terminated after target genes have been activated and not
before. This should involve a mechanism to distinguish
between effectors actively engaged in transcription and those
that are fresh and unused. A modiﬁcation or a change of
conformation of the effectors when they interact with the
target-gene promoter complex may allow recognition by a
critical component of the termination mechanism (referred
to subsequently as the terminator). In this case, absence of the
terminator should lead to a prolonged, persistent response to
signaling, as the unhindered effectors will continue to
transcribe. On the other hand, excess terminator could cause
repression of signaling if it degrades and deactivates the
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promoter. A more precise and efﬁcient mechanism would
involve degradation of the effectors after they activate at least
one round of transcription. This requires a terminator
directly involved in transcription by the effectors or an even
more stringent mechanism, where initiation of transcription
is linked with the destruction of the transcription factor: a
‘‘suicide’’ model. In this case, absence of the terminator will
pause transcription, while its overexpression will not degrade/
deactivate the effectors prematurely to repress target gene
transcription. We show here that Arkadia fulﬁls the criteria of
such a termination mechanism as it degrades P-Smad2/3 and
enhances their target gene transcription via the same
domains.
P-Smad2/3 Activation
Does Arkadia directly activate P-Smad2/3? In the absence
of Arkadia, P-Smad2/3 are stable and accumulate in the
nucleus, but they are repressed or hypoactive as target gene
transcription is reduced and in some cases lost (Figure 7).
Introduction of Arkadia in  /  ES cells not only restores
signaling but super-activates P-Smads, meaning that the
expression of the reporter reaches levels higher than those
that can be achieved in wild-type ES cells under maximum
ligand stimulation conditions. The above ﬁndings suggest that
the extra activity is not generated by receptors or ligands, but
by the release of activity from the pools of the accumulated
hypoactive P-Smad2/3. Consistent with this hypothesis, super-
activation by Arkadia in  /  ES cells is a transient
phenomenon, as it depends on the excess P-Smad2 that is
used up. Therefore, Arkadia degrades and spends P-Smad2/3
to activate their transcriptional activity. These observations
suggest that P-Smad2/3 is reminiscent of fuel, which in the
absence of Arkadia is stable and can be stored, while in its
presence it is ‘‘ignited’’ and ‘‘burns,’’ releasing activity. These
observations suggest that phosphorylation of Smad2/3 by the
receptors is not sufﬁcient for their transcriptional activity
and that they require an additional step mediated by the
function of Arkadia as a coactivator in the nucleus.
We have shown previously that in Xenopus animal cap assay,
injection of Arkadia RNA enhances the ability of Nodal but
not that of Smad2 RNA to induce mesendoderm [40]. This
appears inconsistent with our current data, however; as in the
animal cap there is no ligand to phosphorylate Smad2, it
remains a mystery how Smad2 RNA injection alone induces
mesoderm and mesendoderm. Furthermore, the amount of
Smad2 RNA required for this is very high and most likely does
not represent physiological signaling conditions. More
importantly, we show here that Arkadia recognizes P-Smad2
and not Smad2, and therefore it is not surprising that in the
Smad2-injected animal caps Arkadia does not induce
mesendoderm.
While the exact mechanism of how P-Smad2/3 are activated
by Arkadia remains unknown, it is important to point out
that Arkadia does not degrade P-Smads directly, it only
modiﬁes them by ubiquitination and is the proteasome that
degrades them. Although the role of ubiquitin modiﬁcation
in mediating proteasome degradation is well established, it
has become apparent that addition of ubiquitin onto proteins
may also affect their properties. Recent studies have
suggested a direct role of ubiquitin modiﬁcations and of
the proteasome in transcriptional activation (reviewed in
[60–63]). It is possible, however, that Arkadia interacts with,
and degrades simultaneously, P-Smads and a closely linked
repressor. Future studies will determine the mechanism of P-
Smad2/3 activation and how this is coupled with immediate
degradation. In conclusion, by linking P-Smad2/3 activation
with degradation, Arkadia provides a way to achieve rapid
resetting of P-Smad2/3 target gene transcription in develop-
ment and allows efﬁcient and dynamic responses to Nodal/
TGF-b signaling events.
Nodal Expression and the Induction of the Node/
Organizer
We had shown previously that Arkadia /  embryos do not
develop anterior primitive streak and its derivative tissues:
ADE/future foregut, mesendoderm (prechordal plate and
notochord), and node [39]. However, the molecular mecha-
nisms that underlie these abnormalities were not understood.
Speciﬁcally, we had shown that the formation of the node is
restored in chimeric embryos consisting of tetraploid wild-
type extraembryonic lineages (such as VE) and exclusively
Arkadia /  embryonic tissues derived from  /  ES cells [39].
This indicates that the development of the node in the
embryonic lineages requires Arkadia expression and function
within a different lineage (extraembryonic). As Arkadia is
nuclear and unlikely to be secreted, this effect was presumed
to be mediated by a downstream-secreted factor. Here we
show that Arkadia increases directly the transcription of P-
Smad2 target genes, which include the Nodal gene itself,
particularly in the VE and early epiblast when node
precursors are induced (Figure 7). This suggests that in the
Arkadia /  TC, the wild-type VE provides sufﬁcient Nodal to
partially restore the overall level of Nodal in the Arkadia / 
epiblast, thus bringing it up to the threshold required for
node formation (Figure 7D and unpublished data). Therefore,
organizer/node induction requires high levels of Nodal, which
can be achieved with a considerable contribution from the
VE.
Arkadia in Foregut Development
While the node may be rescued, to what extent expression
of Arkadia in the extraembryonic lineages is sufﬁcient to
restore normal development in the Arkadia /  embryo of the
TC? We show here that these embryos cannot form the most
anterior derivatives of the primitive streak, such as ADE/
foregut and prechordal plate (Figure 7), and exhibit laterality
defects, including delayed turning and heart looping ([39] and
unpublished data). This is consistent with our ﬁndings that
Arkadia is required for efﬁcient P-Smad2/3 target gene
transcription. Speciﬁcally, the reduction of Nodal expression
in the left LPM along with its known target genes (Lefty2 and
Pitx2) can account for the left-right axis defects. The Nodal
target genes that are responsible for foregut and prechordal
plate development remain unknown. However, the develop-
ment of these tissues must depend on the expression of
Arkadia within these cells or their precursors. This was shown
by the analysis of chimeric embryos consisting of a mixture of
wild-type and Arkadia /  cells, which revealed that the  / 
cells could not contribute to these tissues (Figure 7O and 7P).
Furthermore, as Smad2 /  cells [59] and FoxH1 /  cells [58]
behave similarly in chimeras, our data provide in vivo
evidence for the functional interaction between Arkadia
and Smad2, and reveal that the three factors together
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prechordal plate formation.
How Is Maximum Nodal Signaling Achieved?
Our data show that Arkadia is essential for the develop-
ment of tissues that depend on very high Nodal signaling such
as ADE/foregut, and that its introduction in  /  ES cells can
boost signaling above levels obtained by just high concen-
trations of ligand ‘‘super-activation.’’ This latter phenomen-
on is presumably generated by the simultaneous activation of
the accumulated P-Smad2/3, which has been stabilized and
reached higher than normal levels in the absence of Arkadia.
It is possible that such a mechanism may be responsible for
maximizing Nodal signaling in the embryo. However, it would
require the transient absence of Arkadia in the precursors of
the ADE/foregut. Although Arkadia RNA is present broadly in
the embryo, protein analysis is needed to reveal whether
super-activation occurs in the embryo.
In conclusion, we reveal a novel ubiquitin-mediated
mechanism of TGF-b signaling regulation that depends on
Arkadia, involves the activation of P-Smad2/3 signaling
effectors downstream of receptor-phosphorylation, and
couples their high activity with turnover and signaling
termination. As the TGF-b/Nodal signaling pathway has been
linked to cancers and genetic diseases, the identiﬁcation of
key molecular players such as Arkadia would be useful for the
development of new drug targets and therapeutic interven-
tion.
Materials and Methods
Expression analysis. Chimeras were generated as described before
[39]. Both adult mice and embryos were genotyped using allele-
speciﬁc PCR ampliﬁcation of genomic DNA. The oligonucleotide
primer pairs TGAGGTAGGCATACCTAGAG and TGACT-
TAAGCCCTGCAATCC; TGAGGTAGGCATACCTAGAG and
CTGAGTGATTGACTACCCGT; and TCTGGATTCATCGACTGTGG
and CTGGATGTAGGCATGGTTGGTAG were used to give diagnos-
tic ampliﬁcation products of 313 bp for the wild-type Arkadia allele,
293 bp for the disrupted Arkadia allele, and 925 bp for the disrupted
Nodal allele, respectively. Histology and in situ hybridizations and
marker plasmids used are as previously described [39].
RNA extraction and real-time PCR. Total RNA was extracted from
ES cells using Trizol (Invitrogen, http://www.invitrogen.com) followed
by digestion with RQ1 RNase-Free DNase (Promega, http://www.
promega.com) to remove DNA contamination. Synthesis of cDNA
from total RNA was performed with SuperScript II Reverse Tran-
scriptase (Invitrogen). Experiments were performed in quadrupli-
cates using the DNA Engine Opticon Real-Time PCR Detection
System (MJ Research, http://www.bio-rad.com) and SYBRGreen PCR
Master Mix (Applied Biosystems, http://appliedbiosystems.com). The
Nodal 375-bp amplicon was produced by the forward/reverse primer
pair AAGACCAAGCCACTGAGCAT and GCCTTTGCACACAATTT-
CAA. Nodal expression was quantiﬁed by normalizing against
endogenous controls GAPDH (primer pair TGCACCACCAACTGCT-
TAGC and GGCATGGACTGTGGTCATGAG) or YWHAZ (primer
pair CGTTGTAGGAGCCCGTAGGTCAT and TCTGGTTGCGAAG-
CATTGGG) using the delta Ct method.
DNA constructs. Tagged Arkadia: Mus musculus ring ﬁnger 111
(Rnf111) constructs were generated by eliminating the ﬁrst 9 aa of
Arkadia and fusing in frame to GFP (pEGFP-cI; Clontech, http://www.
clontech.com) or Flag-tag (synthetic oligonucleotide). A single Myc-
tag (synthetic oligonucleotide) was fused to the carboxy-terminus of
Arkadia. The various tagged Arkadia sequences and the GFP control
gene were subcloned into SmaI/XhoI of the pTriEx2-hygro (Novagen,
http://www.novagen.com) vector. The Arkadia RING domain muta-
tions were constructed by either deleting the last 24 aa that included
the second Zinc ﬁnger (GAkdR*) or by point mutation leading to
amino acid substitutions (C2–A2) that disrupt both Zinc ﬁngers
(GAkdR2*). GAkdNRG* consists of an internal deletion of the ﬁrst 7
aa of the NRG domain by PCR. The truncated Arkadia containing
only the C-terminal region of Arkadia was constructed by fusing GFP
in frame with the N-terminus of the truncated Arkadias. G-NRG-
RING includes aa 889–989; G-NLS-RING, 903–989; GRING 947–989.
Pitx2-luc and 123-luc (gifts of H. Hamada, Osaka, Japan) and 9xCAGA-
luc; 6 Myc-Smad3; constitutively active forms of Alk4 and Alk6 (gifts
of K. Miyazono, Tokyo, Japan); HA-Ub (gift of Y. Fujita, London,
United Kingdom); and the Flag-Smad2 construct (gift of J. Smith,
Cambridge, United Kingdom).
Cell culture and luciferase assays. The ES cell lines used in this
study were derived directly from blastocysts as described previously
[9]. Subsequently, they were maintained feeder-free in 20% FCS in
DMEM and LIF (Invitrogen). Cells were transiently transfected with
Lipofectamine 2000 (Invitrogen), Lipofectamine Plus (Invitrogen), or
TransIT-293 (Mirus, http://www.mirusbio.com). Arkadia null primary
mouse ﬁbroblasts of mixed 129Sv/MF1 genetic backgrounds were
isolated from embryos at 9.5 dpc and immortalized with pBabe-puro-
SV40-TA (gift from Parmjit Jat, Ludwig Institute, London, United
Kingdom), selected with 0.3 lg/ml puromycin and maintained in F12
(Invitrogen) medium with 20% FCS. Signaling stimulation was
achieved using 50 lng/ml BMP2 or 10 lng/ml Activin A (Sigma,
http://sigmaaldrich.com); signaling inhibition using serine/threonine
kinase inhibitor H7 (Calbiochem, http://www.calbiochem.com) or
SB431542 (Sigma and gift from GSK); and translation inhibition
using 100 lg/ml cycloheximide (Sigma).
Cells were cotransfected with the Fireﬂy reporter plasmids, a
Renilla luciferase transfection control pRL-SV40 (Promega), and
various GFP-tagged Arkadia constructs in a 5:1:5 ratio. Dual luciferase
assays were performed according to manufacturer’s protocols
(Promega) 18 h after transfection, unless stated otherwise. After
normalizing the Fireﬂy values to Renilla, the data was presented as
relative luciferase values or as percent increase.
Protein analysis. For IP studies, cells in 10-cm culture dishes were
treated for 5 h with 50 lM of the proteasome inhibitor MG-132
(Calbiochem) before lysis. The cells were lysed by adding 1 ml per 10-
cm dish of RIPA (150 mM NaCl, 50 mM Tris [pH 8.0], 0.5% DOC,
0.1% SDS, and 1% NP-40) or NP-40 buffer (20 mM Tris [pH 7.5], 150
mM NaCl, 0.5% NP-40), which was speciﬁcally used for the IPs shown
in Figure S5A. Both IP solutions contained 10 mM N-ethylmaleimide
(cysteine protease inhibitor, Sigma), 100 lM MG-132 (Calbiochem),
100 lM Epoxomicin (Calbiochem), 100 lM clasto-Lactacystin b-
Lactone (Calbiochem), and protease/phosphatase inhibitor cocktails
(Sigma) at a ﬁnal concentration of 1% each. After centrifugation at
100,000 g for 30 min, the supernatants were immunoprecipitated for
1 h with the appropriate antibody and 50 ll of protein agarose beads
(Sigma). 2 lg of an anti-GFP mouse monoclonal antibody (clone 7.1
and 13.1; Roche, http://www.roche.com) or 2 lg of the anti-FLAG M2
antibody (Stratagene, http://www.stratagene.com) with 50 llo f
Protein G Sepharose beads (Amersham Biosciences, http://www.
gehealthcare.com) was used for the IP. Samples were eluted off the
beads by boiling in 23 Laemelli buffer followed by standard SDS-
ployacrylamide gel electrophoresis (SDS-PAGE) and Western blot
analysis.
For nuclear and cytoplasmic fractionation, cells were lysed in
hypotonic buffer (20 mM Hepes [pH7.5], 10 mM NaCl, 0.2 mM EDTA,
20% glycerol, 1.5 mM MgCl2, 0.1% Triton X-100) containing protease
and phosphatase inhibitors as above. Nuclei were pelleted by
centrifugation at 1,000 rpm for 10 min, and the cytoplasmic fraction
obtained by retaining the supernatant. Nuclear extracts were
obtained by rocking the nuclear pellet in ﬁve times the volume of
hypertonic solution (hypotonic bufferþ500 mM NaCl) for 1 h at 48 C
and subsequent centrifugation at 13,000 rpm for 5 min. Nuclear
fraction was obtained in the supernatant, and 30 lg of each protein
sample was loaded on each lane. When required to inhibit protein
degradation, MG-132 (50 lM) was added to both the hypotonic and
hypertonic buffers.
Western blot analysis. For Western blotting, cells and embryos
were lysed with the RIPA buffer as for IPs. 30 lg of each protein
sample was loaded on each lane for SDS-PAGE. The following
antibodies were obtained and used according to the manufacturer’s
instructions: rabbit anti-P-Smad2 (Calbiochem), rabbit anti-P-Smad3
(Cell Signaling Technologies, http://www.cellsignal.com and also gift
from E. Leof, Mayo Clinic, United States), rabbit anti-P-Smad1/5/8
(Cell Signaling Technologies), rabbit anti- Smad2 (Zymed Laborato-
ries, http://www.invitrogen.com), rabbit anti-GFP (Abcam, http://
www.abcam.com), rabbit anti- cyclin D2 (H-295; Santa Cruz Bio-
technology, http://www.scbt.com), as well as mouse monoclonal
antibodies against Smad4 (B-8; Santa Cruz); actin (Santa Cruz); PCNA
(PC-10; Santa Cruz); tubulin (B-5-1-2; Sigma); FLAG (M2; Stratagene);
histone H3 (Upstate, http://www.upstate.com); ubiquitin (Covance and
Bethyl Laboratories, http://www.bethyl.com) and HA (Roche).
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35S]-methionine-
labeled or unlabeled recombinant proteins full-length Arkadia, N-
Akd (1–516 aa), C-Akd (510–989), and luciferase were generated by
the TNT Quick Coupled in vitro transcription/translation kit
(Promega). Flag-P-Smad2 was obtained with IP from 293T cells.
Beads bound to Flag-P-Smad2 protein were washed with RIPA buffer
and incubated for 1 h by constant rotation at 4 8C with radiolabeled
recombinant proteins in 1 ml of RIPA buffer. Protein-bead
complexes were then washed four times with RIPA buffer (200 3
bed volume) and re-suspended in 2 3 Laemelli buffer. The presence
of radiolabeled Arkadia protein in pull-downs was detected by SDS-
PAGE and autoradiography. Assays were carried out in 20 llo f
ubiquitination assay buffer (20 mM Tris-HCl [pH7.7], 100 mM KCl,
0.1 mM CaCl2, 1 mM MgCl2, 1 mM DTT) containing 15 lg of GST-
ubiquitin (Boston Biochem, http://www.bostonbiochem.com), 1 lgo f
E1 (Boston Biochem), 1.5 lg of E2 (GSTUbcH5b and GST-UbcH5c;
Boston Biochem), 0.6 ll of Energy Regeneration Solution (Boston
Biochem), and Flag-P-Smad2 immunoprecipitated from 293T cells. In
vitro translated Arkadia and Arkadia mutants (N-terminal corre-
sponding to aa 1–516 and C-terminal truncation corresponding to aa
510–989) were generated using the TNT Quick Coupled in vitro
transcription/translation kit (Promega). Reactions were incubated for
1 h under constant rotation at 37 8C. The reaction was terminated by
the addition of 2 3 Laemelli buffer, and the presence of poly-
ubiquitinated substrates was detected by Western blotting.
Immunoﬂuorescence in ES cells. Immunoﬂuorescence was per-
formed using the following primary antibodies: anti-P-Smad2 anti-
body (1:50; Calbiochem); anti-Smad2/3 (1:100; BD Biosciences, http://
www.bdbiosciences.com); Alexa Fluor 568 anti-rabbit secondary
(1:400; Molecular Probes, http://www.invitrogen.com); and mounting
medium with DAPI (Vectashield, http://www.vectorlabs.com).
Arkadia /  and wild-type ES cells were grown on cover slips and
rinsed in PBS for 5 min prior to ﬁxation with 4% (w/v)
paraformaldehyde in PBS for 10 min. Following ﬁxation, cells were
permeabilized with 0.5% Triton-X 100 in PBS for 2 min on ice and
rinsed with PBS for 5 min and incubated in 10% FCS/PBS for 30 min
to block nonspeciﬁc binding of antibodies. Subsequently, the cells
were incubated with the appropriate primary antibody diluted in
10% FCS/PBS for 1 h at room temperature. A no primary control was
included to verify antibody speciﬁcity. Cover slips were then washed
several times with 10% FCS/PBS and incubated with secondary
antibody for a further 1 h. This was followed by washes in PBS and
cover slips mounted for ﬂuorescence in medium containing DAPI
(Vectashield). The cells were visualized on a Leica TCS SP2 (http://
www.leica.com) confocal microscope at 1003 magniﬁcation.
Supporting Information
Figure S1. P-Smad2/3 Are More Stable in Arkadia Null ES Cells than in
Wild-Type
Western blots of wild-type and Akd / ES cells showing rate of decay
of P-Smad2/3 at different time points during treatment with 10 lM
SB inhibitor (A) or 20 lM H7 inhibitor (B). At point 0* the inhibitors
were added after stimulation with Activin (A and B) and BMP2 (B) for
1 h. Note that the levels of P-Smad2 (A) and P-Smad3 (B) protein at 2
and 3 h in Akd  /  are higher than in wild-type ES cells. Western
blotting with the anti-PCNA antibody show similar amounts of
protein was loaded for each sample. The experiment is reproducible
with different ES cells lines (unpublished data).
Found at doi:10.1371/journal.pbio.0050067.sg001 (757 KB TIF).
Figure S2. The Decay of P-Smad2 Is Slower in Arkadia /  ES Cells in
the Absence of Protein Synthesis
Western blot of Akd / and wild-type ES cells cultured with Activin A
and cycloheximide for different periods in hours (h). Note that P-
Smad2 is more stable in mutant than in wild-type cells, while in both
cell lines Cyclin D2 levels decline similarly and Tubulin remains
stable throughout the treatment.
Found at doi:10.1371/journal.pbio.0050067.sg002 (1.5 MB TIF).
Figure S3. Arkadia Interacts Speciﬁcally with P-Smad2/3 and Not with
P-Smad1/5/8
(A) IP with anti-GFP antibody from 293T cells transfected with
ALK6* and all three myc-Smad1/5/8 plasmids, along with GFP or
GFP-tagged Arkadia constructs as indicated, and Western blotted
with anti-P-Smad1/5/8 or anti-GFP antibodies. Similar levels of P-
Smad protein were present in the total cell lysates (TCL), but were
absent in the IP lanes, indicating lack of interaction. Note the
presence of high molecular weight proteins in the samples with the
various GFP-tagged Arkadias (red arrowhead).
(B) Aliquot of the P-Smad2 protein used for in vitro pull-down
(Figure 3C) and ubiquitination assays (Figure 4C). P-Smad2 isolated
by IP with anti-Flag antibody from 293T cells cotransfected with Flag-
Smad2 and ALK4* or in the presence of SB, and Western blotted with
anti-P-Smad2 antibody. Note that phosphorylated Flag-Smad2 is
present in the IP from cells with Alk4* but not with SB.
(C) Sequence of the C-terminal region of Arkadia (from aa 889 to
terminal 989) containing the NRG domain (blue), a nuclear local-
ization signal (NLS; green), and a RING domain (red). Critical
residues (C3H2C3) comprising the RING domain structure are in red
(cysteines) or blue (histidines).
Found at doi:10.1371/journal.pbio.0050067.sg003 (3.4 MB TIF).
Figure S4. Mutant Arkadia Proteins Localize in the Nucleus or in
Both the Nucleus and Cytoplasm
(A) 293T cells transiently transfected with plasmids expressing GFP-
tagged N-terminal Arkadia deletions.
(B) 293T cells stably expressing GAkd, GAkdR*, or GAkdNRG*.
Confocal microscopy was used to visualize GFP and DAPI nuclear
stain.
Found at doi:10.1371/journal.pbio.0050067.sg004 (6.5 MB TIF).
Figure S5. Arkadia Directly Ubiquitinates P-Smad2
(A) IP with anti-Flag antibody from Akd  /  MEFs transiently
transfected with various plasmids as indicated, and Western blotted
(WB) with anti-P-Smad2, anti-Smad2, or anti-HA antibodies. Note the
presence of higher molecular weight P-Smad2 corresponding to
protein modiﬁcations including ubiquitin chains as shown by the
presence of HA-ubiquitin tags. These are present only in cells
transfected with full-length Arkadia and not with GFP or mutant
forms GAkdR* and GAkdNRG*, which disrupt the ubiquitin ligase
activity and the interaction with P-Smad2, respectively.
(B) Western blot with anti-P-Smad2 and -Ubiquitin antibodies of in
vitro ubiquitination reactions containing various components as
indicated. Arkadia was generated from reticulocyte extracts and Flag-
P-Smad2 protein derived from 293T cells transiently transfected with
Flag-Smad2 and Alk4* (Figure S3B). Note the increase of high
molecular weight Flag-P-Smad2 forms only in the reaction containing
Arkadia. The presence of high molecular weight ubiquitinated
proteins in the reaction containing Arkadia without P-Smad2
indicates that Arkadia self-ubiquitinates, while the presence of more
ubiquitinated forms in the reaction that contains both Arkadia and
P-Smad2 indicates that both proteins are ubiquitinated.
Found at doi:10.1371/journal.pbio.0050067.sg005 (3.0 MB TIF).
Figure S6. Arkadia Null TCs Exhibit Prechordal Plate Deﬁcit
In situ hybridization with Shh riboprobe on 9.5 dpc (WT, A and C)
and TC (B and D). (C and D) Section level of the embryos shown in (A
and B) is indicated by the blue line. Note in the TC the head
truncation and the reduction of Shh expression in the anterior region
corresponding to the prechordal plate (B), the presence of notochord
(NC), and aberrant gut tube endoderm (GE) in (D).
Found at doi:10.1371/journal.pbio.0050067.sg006 (5.0 MB TIF).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/genbank) accession num-
bers for the entities from the discussed in this paper are Arkadia
(NM_033604), GAPDH (NM_001001303), Nodal (NM_013611), and
YWHAZ (NM_011740).
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